SAN DIEGO—Certis Oncology Solutions and Reveal Biosciences have formed a strategic partnership under which the two companies will collaborate to provide what they call “an innovative, next-generation suite of preclinical oncology services.” Reveal will leverage its artificial intelligence (AI)-based pathology tools to generate advanced analytics that quantify biomarkers in human tumor tissue grown in immunodeficient mice using Certis’ Orthotopic PDX (patient-derived xenograft) technique. The combined services will also feature Tissue Micro Arrays, which enable multiple Orthotopic PDX tumors to be analyzed at the same time.

 

“We have been working closely with Certis for some time and are delighted to formalize the relationship,” said Dr. Claire Weston, founder and CEO of Reveal Biosciences. “With their ability to grow Orthotopic PDX tumors in mice at a high rate and replicate patient outcomes, Certis mouse models are more clinically relevant than standard PDXs. This provides a critical new class of data for cancer drug development.”

 

“Reveal’s quantitative histopathology services and AI-based pathology analysis provide an ideal foundation for researching the characteristics of Orthotopic PDX-based tumors,” added Peter Ellman, CEO of Certis Oncology. “Their AI-based tissue analysis utilizes trained pathology models to recognize disease patterns and quantify biomarkers in whole slide digital images to benefit translational oncology research.”

 

Reveal Biosciences is not only helping to pioneer the next generation of quantitative histopathology, but is also generating disease-specific AI-based models as pathology decision support diagnostics to benefit patients and accelerate clinical trials. Certis, for its part, is a new precision medicine company.